Arab Drug’s board approves Q1 FY 2021/2022 preliminary financial results  

Updated 10/15/2021 12:02:14 AM

ArabFinance: The Arab Drug Company (ADCI) announced that its board of directors has approved the preliminary financial results for the period from July 1st to September 30th, 2021, according to a statement filed to the Egyptian Exchange (EGX).

The company’s net profit before tax amounted to EGP 33.125 million in the three-month period ended September 30th, 2021, compared to a profit of EGP 30.935 million in the year-ago period.

Meanwhile, the company’s net sales valued at EGP 150.762 million in the July-September period of 2020, compared to EGP 148.757 million in the same period of 2020.

Arab Drug is an Egypt-based company engaged in the pharmaceutical sector. The company focuses on the manufacture, packaging, and distribution of pharmaceutical products as well as chemical solutions for human and veterinary use.